Who Gets the Return in Drug Development?
Impossible d'ajouter des articles
Échec de l’élimination de la liste d'envies.
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Who Gets the Return in Drug Development?
-
Lu par :
-
De :
À propos de ce contenu audio
Click here to watch a video of this episode.
In drug development, ROI debates can drown out decision-grade evidence and the hard work of translational science. This episode asks a blunt question: when AI, digital biomarkers, or new assays change the work, who actually gets the return and who carries the downside? The tension is that finance wants clean numbers, while biology delivers messy truth. We challenge the habit of treating ROI as a single scoreboard and propose a more honest framing: financial return, return on intention for patients, and return on learning for the next decision. When those diverge, teams optimize for optics. When they align, innovation becomes durable and defensible. Takeaway: define your returns explicitly and report them side by side at governance meetings, before you declare a “win.”
Vous êtes membre Amazon Prime ?
Bénéficiez automatiquement de 2 livres audio offerts.Bonne écoute !
